Prostate Cancer and Prostatic Diseases

Papers
(The TQCC of Prostate Cancer and Prostatic Diseases is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The imperative for clinical trial diversity: Perspectives in the context of prostate-specific membrane antigen-targeted imaging134
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?106
Integrating clinical and public health perspectives on statin use and prostate cancer risk: addressing key limitations and future directions104
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer90
Best of 2022 in prostate cancer and prostatic diseases75
New BPH therapy classification: what really FITs?71
Will generalist medical artificial intelligence be the future path for health-related natural language processing models?63
A randomized controlled trial evaluating low-intensity shockwave therapy for treatment of persistent storage symptoms following transurethral surgery for benign prostatic obstruction59
Sexual outcomes in men who have sex with men who underwent radical prostatectomy58
Prognostic value of a baseline prognostic nutritional index for patients with prostate cancer: a systematic review and meta-analysis54
Focal radiation therapies for localized prostate cancer: a systematic review of clinical evidence and outcomes45
Perioperative outcomes of HoLEP, ThuLEP, and TURP in patients with prostate cancer: results from the GRAND study44
Functional outcomes and safety of focal therapy for prostate cancer: a systematic review on results and patient-reported outcome measures (PROMs)43
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or andro43
Concerns regarding prostate cancer screening guidelines in minority populations42
Hypofractionated radiotherapy in elderly patients (≥75 years) affected by localized prostate cancer: a multicenter retrospective analysis from the IPOPROMISE study41
DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer: prespecified third interim analysis40
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations39
Concurrent prognostic utility of lymph node count and lymph node density for men with pathological node-positive prostate cancer39
Feasibility and safety study of the Flostent™ system (RAPID-I)37
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancer37
Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study36
Perceived patient burden and acceptability of MRI in comparison to PSA and ultrasound: results from the IP1-PROSTAGRAM study36
Prostate cancer and podcasts: an analysis and assessment of the quality of information about prostate cancer available on podcasts35
Disease progression patterns and association of prostate-specific antigen level with risk of progression in nonmetastatic castration-resistant prostate cancer35
Correction: Application of next-generation imaging in biochemically recurrent prostate cancer34
TRexit is going one step further33
Use of a Schelin catheter for transurethral intraprostatic anesthesia (TUIA) prior to iTIND procedure33
Incidence of prostate cancer in transgender women in the US: a large database analysis32
Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients32
Prospective comparison of restriction spectrum imaging and non-invasive biomarkers to predict upgrading on active surveillance prostate biopsy32
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons31
Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database30
Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms30
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesions29
A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer29
“Targeted microwave ablation: another way to kick the can(cer) down the road?”27
Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis27
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials27
Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants26
Reply to RE: Can ChatGPT provide high-quality patient information on male lower urinary tract symptoms suggestive of benign prostate enlargement?25
Methodological concerns regarding KEYNOTE-199: immortal time bias and treatment attribution challenges in combination immunotherapy25
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort24
Antimicrobial prophylaxis: To do or not to do? This is the question24
The times have changed. Let the urologists change!24
A nationwide histopathology study reflecting the impact of the introduction of MRI in the diagnostic trajectory of prostate cancer in routine clinical care23
Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis23
Avoiding unnecessary biopsy: the combination of PRIMARY score with prostate-specific antigen density for prostate biopsy decision23
Prostate biopsy - current discussions and future perspectives23
Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study23
Treatment decision-making among patients with metastatic prostate cancer: Impact of decision locus of control on functional outcomes and decision satisfaction23
High GLUT1 membrane expression and low PSMA membrane expression in Ductal Adenocarcinoma and Intraductal Carcinoma of the prostate22
Correction to: Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases22
Correction: Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer22
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies22
The effects of glycemic index on prostate cancer progression in a xenograft mouse model22
Editorial Expression of Concern: Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells22
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK21
Association of prostate cancer with human papillomavirus infections: a case-control study21
Prostate cancer screening and management in patients candidate for endoscopic enucleation of the prostate: an international survey21
Novel non-MRI imaging techniques for primary diagnosis of prostate cancer: micro-ultrasound, contrast-enhanced ultrasound, elastography, multiparametric ultrasound, and PSMA PET/CT21
Survivorship in prostate cancer following robotic assisted radical prostatectomy–the time to act is now!21
Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis20
Established focal therapy—HIFU, IRE, or cryotherapy—where are we now?—a systematic review and meta-analysis20
A healthy diet, a healthy prostate? A brief commentary on the latest research on diet and prostate cancer20
Prognostic value of MR visibility/invisibility in men on Active Surveillance20
Perioperative outcomes comparing the DaVinci 5 with DaVinci Xi in patients undergoing robotic-assisted radical prostatectomy19
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients—towards a tumor volume-based risk stratification19
Correction to: Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan19
The relative impact of lymph-node metastasis and seminal vesical invasion on oncologic outcomes following radical prostatectomy19
Re: Endoscopic enucleation of the prostate versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review and meta-analysis18
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer18
Yoga, benign prostatic hyperplasia and lower urinary tract symptoms: a new path for clinical trials18
Sleep disturbances are underappreciated in prostate cancer survivorship18
A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer18
Response to correspondence regarding “The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study”18
Top-down holmium laser enucleation of the prostate (HoLEP) versus traditional HoLEP for the treatment of benign prostatic hyperplasia (BPH): 1-year outcomes of a randomized controlled trial18
Risk calculators for the detection of prostate cancer: a systematic review18
Practical management of hematuria after endoscopic surgery for benign prostatic obstruction18
Revisiting ADT in mCRPC: balancing oncologic control and mitochondrial implications17
Correction: Editorial comment on “Reevaluating ‘Top-Down’ HoLEP: the case for anterior fibromuscular stroma as a surgical landmark”17
Is extended pelvic lymph node dissection REALLY required for staging of prostate cancer in the PSMA-PET era?17
The diagnosis and treatment of castrate-sensitive oligometastatic prostate cancer: A review17
Less is more: the “Safety Net Approach” balances precision and safety17
Cardiovascular risk in ADT recipients: does the type of ADT matter?17
Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy16
Characteristics of incidental prostate cancer in the United States16
Prevalence and determinants of shared decision-making for PSA testing in the United States15
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey15
Comparison of procedural anxiety and pain associated with conventional transrectal ultrasound prostate biopsy to magnetic resonance imaging-ultrasound fusion-guided biopsy: a prospective cohort trial15
Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI15
Real-world analysis of androgen receptor inhibitors in US patients with nonmetastatic castration-resistant prostate cancer: DEAR-EXT study15
The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis15
5 T versus 3 T MRI for prostate cancer: an intra-individual prospective comparison of image quality and diagnostic performance15
Negative perceptions of the health system and racial inequities in PSA screening15
MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis15
Potential miscommunication of risk in American College of Radiology Prostate Imaging and Data System (PIRADS) scores15
Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis15
MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed14
Feasibility and safety of single-port transvesical simple prostatectomy in patients with very large prostates: A volume-stratified analysis14
Focal therapy for localized prostate cancer: not all that glitters is gold14
Antifibrotic therapy for Lower Urinary Tract Symptoms secondary to Benign Prostatic Hyperplasia14
Influence of anterior fibromuscular stroma on incontinence outcomes in RASP and HoLEP: a critical analysis of Grosso et al.‘s findings13
Bridging the gap between PSMA-PET and reality: critical missing elements in AR-guided pelvic lymph node dissection13
Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer13
Shifting the paradigm in high-risk prostate cancer: how good is TNM alone?13
Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis13
Intraoperative technologies to assess margin status during radical prostatectomy – a narrative review13
The impact of race on survival in metastatic prostate cancer: a systematic literature review13
Best of 2023 in Prostate Cancer and Prostatic Diseases13
Quality of information and appropriateness of ChatGPT outputs for urology patients12
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients12
Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)12
The changing face of castrate resistant prostate cancer12
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with doceta12
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting12
Biopsy strategies in the era of mpMRI: a comprehensive review12
Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?12
Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations12
Characterizing population-wide genomic risk distribution for development of a novel clinical-genomic risk system for prognostication in patients with clinically localized prostate cancer12
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis12
Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis12
Overcoming barriers to prostate cancer genetic testing: who, when, and how12
Interpreting undetectable PSA and surveillance inference in post hoc ARAMIS analyses12
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomiz12
Hyperglycemia and microRNAs in prostate cancer12
Fecal incontinence after prostate cancer irradiation: a systematic literature review11
Retzius-sparing vs. standard robot-assisted radical prostatectomy for clinically localised prostate cancer: a comparative study11
The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancer11
Androgen deprivation therapy for prostate cancer and neurocognitive disorders: a systematic review and meta-analysis11
The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study11
Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH11
Quality of information and appropriateness of Open AI outputs for prostate cancer11
Surveillance after Focal Therapy – a Comprehensive Review11
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis11
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment11
Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry11
MISTs for benign prostatic hyperplasia as first line interventional treatment: Alea iacta est?11
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration11
The value of micro-ultrasound for prostate cancer screening: A retrospective real-world feasibility study11
Exploring the utility of artificial intelligence in identifying progression of prostate cancer during active surveillance: A systematic review11
0.14215517044067